Stocks · News reference

Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $38

Aug 3, 2026, 9:28 PMBenzinga Newsdesk

Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $37 to $38.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 3, 2026, 9:28 PM
Checked: Aug 3, 2026, 9:28 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 13, 2026, 7:06 PMBenzinga Newsdesk
Pharming Group shares are trading higher after the company announced the commercial launch of Joenja in Japan for adult and pediatric patients with activated PI3K delta syndrome aged 4 years and older.
Read original at benzinga
PHAR
BenzingaAug 13, 2026, 5:07 AMBenzinga Newsdesk
Pharming Launches Joenja (Leniolisib) in Japan for APDS Patients Aged 4 and Older, Marking First Global Launch for Children 4 To 11
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwideOrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan
Read original at benzinga
PHAR
BenzingaJul 30, 2026, 5:27 PMBenzinga Newsdesk
Pharming shares are trading lower after the company reported Q2 financial results and lowered its FY26 sales guidance below analyst estimates.
Read original at benzinga
PHAR